Submitted by ljc4002 on August 21, 2025 - 2:26pm
| Title | The Tuberculosis Drug Accelerator at year 10: what have we learned? |
| Publication Type | Journal Article |
| Year of Publication | 2021 |
| Authors | Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V, Duncan K, Fotouhi N, Gusovsky F, Hipskind PA, Kempf DJ, Lelièvre J, Lenaerts AJ, McNamara CW, Mizrahi V, Nathan C, Olsen DB, Parish T, H Petrassi M, Pym A, Rhee KY, Robertson GT, Rock JMichael, Rubin EJ, Russell B, Russell DG, Sacchettini JC, Schnappinger D, Schrimpf M, Upton AM, Warner P, Wyatt PGraham, Yuan Y |
| Journal | Nat Med |
| Volume | 27 |
| Issue | 8 |
| Pagination | 1333-1337 |
| Date Published | 2021 Aug |
| ISSN | 1546-170X |
| Keywords | Antitubercular Agents, Drug Design, Humans, Learning, Time Factors, Tuberculosis |
| Abstract | The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in TB drug discovery by breaking down barriers among competing labs and institutions, has reached the 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for application of similar models to other diseases. |
| DOI | 10.1038/s41591-021-01442-2 |
| Alternate Journal | Nat Med |
| PubMed ID | 34226736 |
| PubMed Central ID | PMC10478072 |
| Grant List | Z99 AI999999 / ImNIH / Intramural NIH HHS / United States |